4Nygard O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile: The Hordaland homocysteine study [J]. JAMA, 1995(274): 1526-1533.
3Vermeulen EG, Rauwerda JA, van den Berg M, et al. Homocysteine-lowefing treatment with folic acid plus vitamin 136 lowers urinary albumin excretion but not plasma markers of endothelial function or C-reactive protein:further analysis of secondary end-points of a randomized clinical trial [ J ]. Eur J Clin Invest,2003,33 ( 3 ) : 209-215.
4Geisel J, Hennen B, Hubner U, et al. The impact of hyperhomocysteinemia as a cardiovascular risk factor in the prediction of coronary heart disease[ J]. Clin Chem Lab Med ,2003,41 ( 11 ) : 1513-1517.
5Kartal Ozer N, Negis Y, Aytan N. Molecular mechanisms of cholesterol or homocysteine effect in the development of atherosclerosis: Role of vitamin E [ J ]. Biofactors, 2003,19 ( 1/2 ) :63-70.
7Mujumdar VS, Tummalapalli CM, Aru GM, et al. Mechanism of constrictive vascular remodeling by homocysteine: role of PPAR [ J ]. Cell physiology, 2002,282 ( 5 ) : C 1009 -C 1015.
8Yoo JH, Choi GD, Kang SS. Pathogenicity of thennolabile methylenetetrahydrofolate reductase for vascular dementia [ J ]. Arterioscler Thromb Vase Biol,2000,20(8) :1921-1925.
9Sydorskyy Y, Dilworth D J, Yi EC, et al. Intersection of the Kap123p-mediated nuclear import and ribosome export pathways [ J ]. Mol Cell Biol,2003,23 (6) :2042-2054.
10Boysen G, Brander T, Christensen H, et al. Homocysteine and risk of recurrent stroke[ J]. Stroke ,2003,34(5 ) :1258-1261.
